Progenity to Participate in the 32nd Annual Piper Sandler Healthcare Conference
Progenity, Inc. (Nasdaq: PROG) announced that CEO and co-founder Harry Stylli, Ph.D., will participate in a fireside chat at the Piper Sandler Healthcare Conference from December 1-3, 2020. The pre-recorded chat will be accessible starting November 23, 2020, on the company's website, where it will remain available through December 3. Progenity specializes in developing and commercializing molecular testing products aimed at improving healthcare outcomes through precision medicine and multi-omics approaches.
- None.
- None.
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that Harry Stylli, Ph.D., CEO, chairman of the board, and co-founder of Progenity, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference, being held December 1-3, 2020.
The pre-recorded fireside chat will be accessible beginning November 23, 2020 by visiting progenity.com/presentations. The recording will be available on the Progenity website through December 3, 2020.
About Progenity
Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For additional information about Progenity, please visit the company’s website at www.progenity.com.
Investor Contact:
Robert Uhl
Managing Director, Westwicke ICR
ir@progenity.com
(619) 228-5886
Media Contact:
Kate Blom-Lowery
CG Life
media@progenity.com
(858) 457-2436
FAQ
When will Harry Stylli participate in the Piper Sandler Healthcare Conference?
How can I access the fireside chat with Progenity's CEO?
What is the main focus of Progenity's molecular testing products?
What is Progenity's stock symbol?
